Ocugen to Present at the GCFF Virtual Conference - Diversified Investing Strategies
October 29 2020 - 8:45AM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing transformative
therapies to cure blindness diseases, today announced it will
present at the Global Chinese Financial Forum (GCFF) Virtual
Conference—Diversified Investing Strategies on November 5 at
1:45 p.m. Eastern Time.
Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder
will present virtually to provide an update on the development of
Ocugen’s breakthrough modifier gene therapy platform as well as its
novel biologic product candidate. He will highlight Ocugen’s lead
product candidate, OCU400 including its four FDA orphan drug
designations and its potential to treat broad Retinitis Pigmentosa,
which has over 150 gene mutations. In addition, he will discuss
Ocugen’s strategic manufacturing partnership with Tianjin-based
CanSino Biologics Inc., and their opportunity to develop,
manufacture and commercialize OCU400 for Greater China Market. Dr.
Musunuri will share Ocugen’s recent accomplishments including its
recent engagement of Kemwell Biopharma for cGMP Manufacture of
OCU200, Ocugen’s biologic product candidate in preclinical
development for treating severely sight-threatening diseases like
Diabetic Macular Edema, Diabetic Retinopathy, and Wet Age-Related
Macular Degeneration. With China leading the world in diabetes
cases, OCU200 could have the potential to help those suffering from
diabetes-related eye diseases.
Presentation
Details:Date: Thursday, November 5,
2020Time: 1:45 PM (Eastern Time)
The GCFF Virtual Conference—Diversified Investing
Strategies will take place on November 5 virtually. GCFF is the
largest conference that caters towards the Chinese investment
community in North America. Registration is free. For more
information and to register, please visit:
https://gcff-nov-2020-en.eventbrite.ca/?aff=PR.
About Ocugen, Inc.Ocugen, Inc. is
a biopharmaceutical company focused on discovering, developing, and
commercializing transformative therapies to cure blindness
diseases. Our breakthrough modifier gene therapy platform has the
potential to treat multiple retinal diseases with one drug – “one
to many” and our novel biologic product candidate aims to offer
better therapy to patients with underserved diseases such as wet
age-related macular degeneration, diabetic macular edema, and
diabetic retinopathy. For more information, please visit
www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (the “SEC”), including the
risk factors described in the section entitled “Risk Factors” in
the quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Corporate
Contact:Ocugen, Inc.Sanjay SubramanianChief
Financial Officerir@ocugen.comMedia Contact:
LaVoieHealthScience Katie
Gallagherkgallagher@lavoiehealthscience.com+1 617-792-3937
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2023 to Apr 2024